Stock market analysts have maintained ‘buy’ rating on Jubilant Organosys Ltd with an intraday target of Rs 300.

According to them, interested traders can purchase the stock above Rs 293 with a strict stop loss of Rs 288. If the stock markets remain on the positive path then the stock price will hit a target above Rs 325.

Shares of the company, on Thursday (Nov 12), closed at Rs 288.90 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 321.10 and a low of Rs 85 on BSE. Current EPS & P/E ratio of the stock stood at 22.45 & 12.56 respectively.

Duke University and Jubilant Organosys through its division, Jubilant Biosys, on Nov 10, signed up a LoI in order to build up a multi-faceted joint venture, which will accelerate translation of findings made by Duke researchers into clinical therapies.

The said affiliation will also encourage mutual obligation between both organizations to lessen worldwide health inequalities.

The companies shall complete definitive deals by the first quarter of 2010.

Drug manufacturer Jubilant Organosys on Nov 08 announced that it has reserved Rs 250 crore to strengthen its overall capacity during the existing fiscal.

Shyam S Bhartia, Jubilant Organosys Chairman and Managing Director, said that a big part of it would be spent on de-bottlenecking actions whereas a small percentage of it would go for the research & development activities.

Jubilant Organosys, during Oct 2009, declared that it would lift up Rs 5 billion.

The company also announced that it would be diverting application polymers section and consumer products division.

Moreover, the company also announced that it would shortly change the company’s name from `Jubilant Organosys` to `Jubilant Life Sciences`.